Advent Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Advent Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-150	Closed	-$8K	–	275
2017 Q3	$8K	Buy	+150	New	+$13.3K	﹤0.01%	260
2016 Q2	–	Sell	-420	Closed	-$8K	–	460
2016 Q1	$8K	Buy	+420	New	+$34.2K	﹤0.01%	413
2015 Q1	–	Sell	-172	Closed	-$5K	–	472
2014 Q4	$5K	Buy	+172	New	+$14.3K	﹤0.01%	467
2014 Q3	–	Sell	-200	Closed	-$11K	–	467
2014 Q2	$11K	Buy	+200	New	+$12.1K	﹤0.01%	458

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Advent Capital Management's BMRN Position: Q1 2021 in Review

Advent Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 4,520 shares — an estimated $396K sold.

Advent Capital Management first reported a position in BMRN in Q2 2013 and held it in 16 quarters. The position peaked at $6.62M in Q1 2015. 531 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

Advent Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Advent Capital Management sold 4,520 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $396K.
Advent Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Advent Capital Management's BioMarin Pharmaceuticals position peaked at $6.62M in Q1 2015.
531 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Advent Capital Management's 13F filing for Q1 2021, filed 17 May 2021.